Trimodulin supports antibacterial defence and restricts inflammation in preclinical pneumonia models.

BACKGROUND

Severe community-acquired pneumonia remains a global health challenge with high mortality despite advances in antibiotic therapy and supportive care. Immunoglobulin therapies, especially IgM-containing ones, have shown promise in enhancing host defence and reducing inflammation. The CIGMA trial highlighted the potential of trimodulin to lower mortality in patients with severe community-acquired pneumonia with high C-reactive protein and low IgM levels.

METHODS

We investigated the protective effects of trimodulin on clinical status, bacterial burden, lung integrity and inflammatory responses in murine models of lung injury, including both ventilator-induced lung injury and infection-induced models with nonsterile inflammation.

RESULTS

In mice, trimodulin significantly protected against lethal pneumococcal pneumonia by reducing bacterial burden and disease severity while preserving alveolar barrier integrity and limiting lung oedema. The antibacterial action of trimodulin was mediated through opsonophagocytosis, and its anti-inflammatory effects operated independently of the latter. When combined with ampicillin, trimodulin exhibited enhanced suppression of inflammation.

CONCLUSION

Our findings in preclinical pneumonia models suggest that trimodulin could be a promising therapy for severe community-acquired pneumonia. We provide evidence that trimodulin enhances host defence, reduces detrimental pulmonary inflammation and barrier dysfunction, and limits pulmonary oedema, which may explain the beneficial effects observed in patients with severe community-acquired pneumonia.